Core Viewpoint - Yiming Anke-B (01541) has received approval from the National Medical Products Administration of China for clinical trials of IMM01 (Tadapaxip) for the treatment of atherosclerosis, which has positively impacted its stock price [1][4]. Group 1: Company Developments - Yiming Anke's stock price increased by 9.28% to HKD 6.71, with a trading volume of HKD 12.32 million [1][4]. - The company holds global intellectual property and commercialization rights for IMM01 (Tadapaxip), with a patent family that includes authorized patents in China, the United States, Japan, and the European Union [1][4]. Group 2: Research and Development Insights - Guoyuan International reported that the company has regained global rights for IMM2510 and IMM27M, which will accelerate its overseas clinical research and development pace [1][4]. - Clinical data for IMM2510 is reported to be excellent, with good safety and significant differentiation advantages [1][4]. - The company has a rich R&D pipeline, enhancing its risk resistance, with promising clinical efficacy data for the CD47CD20 dual antibody (IMM0306), which is expected to become a key drug in the autoimmune field [1][4]. - The company is recognized as a global innovator in CD47 fusion proteins, with broad application prospects in oncology, autoimmune diseases, and cardiovascular fields [1][4]. - The current market capitalization is only HKD 2.7 billion, indicating a significant undervaluation, and it is recommended to pay close attention to the company [1][4].
宜明昂科-B午前涨超9% 机构指公司价值严重低估建议积极关注